14.05

2.29% -0.33

After Hours: 13.62 -0.43 -3.06%

Replimune Group Inc (REPL)

Overview News Price History Option Chain Financials Discussions Forecast

Replimune Group Inc stock is traded at $14.05, with a volume of 1.30M. It is down -2.29% in the last 24 hours and up +19.78% over the past month. Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.

Previous Close:

$14.38

Open:

$14.38

24h Volume:

1.30M

Relative Volume:

1.62

Market Cap:

$955.79M

Revenue:

Net Income/Loss:

$-209.96M

P/E Ratio:

-4.7306

EPS:

-2.97

Net Cash Flow:

$-176.27M

1W Performance:

+25.11%

1M Performance:

+19.78%

6M Performance:

+169.16%

1Y Performance:

+32.17%

1-Day Range:

$13.79

$14.64

1-Week Range:

$11.00

$17.00

52-Week Range:

$4.92

$17.00

Replimune Group Inc Stock (REPL) Company Profile

Name

Replimune Group Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

(781) 222-9600

Address

500 UNICORN PARK, WOBURN, MA

Employee

331

Twitter

@Replimune

Next Earnings Date

2024-11-05

Latest SEC Filings

REPL's Discussions on Twitter

Compare REPL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
REPL Replimune Group Inc	14.05	955.79M	0	-209.96M	-176.27M	-2.97
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Replimune Group Inc Stock (REPL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-28-24	Initiated	ROTH MKM	Buy
Apr-17-23	Resumed	Piper Sandler	Overweight
Nov-19-21	Initiated	Piper Sandler	Overweight
Oct-15-21	Resumed	BTIG Research	Buy
Nov-17-20	Initiated	BTIG Research	Buy
Nov-02-20	Initiated	Jefferies	Buy
Oct-15-20	Upgrade	H.C. Wainwright	Neutral → Buy
Jul-01-20	Downgrade	H.C. Wainwright	Buy → Neutral
May-05-20	Initiated	Barclays	Overweight
Sep-04-19	Initiated	ROTH Capital	Buy
Jul-23-19	Initiated	Chardan Capital Markets	Buy
Jul-12-19	Upgrade	JP Morgan	Neutral → Overweight
Jul-08-19	Initiated	H.C. Wainwright	Buy
Apr-25-19	Initiated	Wedbush	Outperform
Jan-23-19	Downgrade	JP Morgan	Overweight → Neutral
Aug-14-18	Initiated	JP Morgan	Overweight
Aug-14-18	Initiated	Leerink Partners	Outperform

View All

Replimune Group Inc Stock (REPL) Latest News

Nov 26, 2024

Replimune announces $125 million public offering By Investing.com - Investing.com South Africa

Nov 26, 2024

Replimune's SWOT analysis: stock outlook as RP1 nears key milestones By Investing.com - Investing.com Canada

Nov 26, 2024

Replimune Announces Pricing of Upsized Public Offering - The Manila Times

Nov 26, 2024

Replimune Prices $140M Upsized Public Offering of Common Stock & Warrants | REPL Stock News - StockTitan

Nov 26, 2024

Nov 25, 2024

Replimune Announces Pricing of Upsized Public Offering - GlobeNewswire Inc.

Nov 25, 2024

Replimune's SWOT analysis: stock outlook as RP1 nears key milestones - Investing.com

Nov 25, 2024

How to Take Advantage of moves in (REPL) - Stock Traders Daily

Nov 25, 2024

Replimune announces $125 million public offering - Investing.com India

Nov 25, 2024

Replimune Announces Proposed Public Offering - The Manila Times

Nov 25, 2024

Replimune Announces $125M Public Stock Offering, Plans Additional Securities Option | MOBX Stock News - StockTitan

Nov 25, 2024

Canadian Dollar/Japanese Yen (CADJPY) QuotePress Release - The Globe and Mail

Nov 25, 2024

Replimune Group (NASDAQ:REPL) Price Target Raised to $18.00 - Defense World

Nov 25, 2024

Nov 24, 2024

Replimune Group (NASDAQ:REPL) Earns Buy Rating from HC Wainwright - Defense World

Nov 24, 2024

Nov 23, 2024

Replimune's stock surges 19% after-hours on FDA BLA submission - MSN

Nov 23, 2024

Replimune Group (NASDAQ:REPL) Hits New 12-Month High After Analyst Upgrade - MarketBeat

Nov 23, 2024

BMO Capital Markets Raises Replimune Group (NASDAQ:REPL) Price Target to $18.00 - MarketBeat

Nov 23, 2024

Replimune Group (NASDAQ:REPL) Has Debt But No Earnings; Should You Worry? - Simply Wall St

Nov 23, 2024

Nov 22, 2024

Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug - Yahoo Finance

Nov 22, 2024

Replimune stock target lifted, outperform on BLA submission By Investing.com - Investing.com UK

Nov 22, 2024

Replimune Group (NASDAQ:REPL) Receives "Buy" Rating from HC Wainwright - MarketBeat

Nov 22, 2024

Replimune stock climbs after updates on RP1 (REPL:NASDAQ) - Seeking Alpha

Nov 22, 2024

Replimune's stock surges 19% after-hours on FDA BLA submission By Investing.com - Investing.com Australia

Nov 22, 2024

Replimune seeks FDA approval for melanoma treatment By Investing.com - Investing.com Canada

Nov 22, 2024

Analyzing MiNK Therapeutics (NASDAQ:INKT) & Replimune Group (NASDAQ:REPL) - Defense World

Nov 22, 2024

After-Hour Trading Boosts Replimune (REPL) Amid Regulatory Success - Stocks Telegraph

Nov 22, 2024

Nov 21, 2024

Replimune Group Advances Cancer Treatment with FDA Submission - TipRanks

Nov 21, 2024

Replimune Shares Top 52-Week High After Submitting Application for Melanoma Treatment - MarketWatch

Nov 21, 2024

Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway - The Manila Times

Nov 21, 2024

Replimune seeks FDA approval for melanoma treatment - Investing.com

Nov 21, 2024

Replimune Seeks FDA Approval for Breakthrough Melanoma Treatment RP1 | REPL Stock News - StockTitan

Nov 21, 2024

Replimune's chief commercial officer sells $56,131 in stock By Investing.com - Investing.com Nigeria

Nov 21, 2024

Nov 20, 2024

Replimune group's chief medical officer sells shares worth $78,111 By Investing.com - Investing.com Canada

Nov 20, 2024

Replimune group's chief medical officer sells shares worth $78,111 - Investing.com India

Nov 20, 2024

Replimune's chief commercial officer sells $56,131 in stock - Investing.com

Nov 20, 2024

REPL (Replimune Group) Peter Lynch Fair Value : N/A (As of Nov. 20, 2024) - GuruFocus.com

Nov 20, 2024

Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by LMR Partners LLP - MarketBeat

Nov 20, 2024

Nov 17, 2024

Replimune Group Q3 EPS Forecast Decreased by Leerink Partnrs - Defense World

Nov 17, 2024

Nov 15, 2024

What is Wedbush's Estimate for Replimune Group Q3 Earnings? - MarketBeat

Nov 15, 2024

HC Wainwright Predicts Stronger Earnings for Replimune Group - MarketBeat

Nov 15, 2024

Leerink Partnrs Weighs in on Replimune Group Q3 Earnings - MarketBeat

Nov 15, 2024

Significant Stake Increase by Baker Bros. Advisors in Replimune Group Inc - GuruFocus.com

Nov 15, 2024

Brokerages Set Replimune Group, Inc. (NASDAQ:REPL) Target Price at $16.80 - Defense World

Nov 15, 2024

Nov 14, 2024

When (REPL) Moves Investors should Listen - Stock Traders Daily

Nov 14, 2024